Pasar al contenido principal

USO DE MODELOS 3D DERIVADOS DE PACIENTES PARA DESARROLLAR NUEVAS ESTRATEGIAS TERAPEUTICAS CAPACES DE REVERTIR LA RESISTENCIA A TRATAMIENTOS ANTI-TUMORALES EN SARCOMAS OSEOS

PID2022-142020OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PARA LA INVESTIGACION E INNOVACION BIOSANITARIA EN EL PRINCIPADO DE ASTURIAS

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma

  • Rey, Verónica
  • Tornín, Juan
  • Alba-Linares, Juan J.
  • Robledo, Cristina
  • Murillo, Dzohara
  • Rodríguez, Aida
  • Gallego, Borja
  • Huergo, Carmen
  • Viera, Cristina
  • Braña, Alejandro
  • Astudillo, Aurora
  • Heymann, Dominique
  • Szuhai, Karoly
  • Bovée, Judith V.M.G.
  • Fernández, Agustín F.
  • Fraga, Mario F.
  • Alonso, Javier
  • Rodríguez, René
[Background]: Sarcomas represent an extensive group of malignant diseases affecting mesodermal tissues. Among sarcomas, the clinical management of chondrosarcomas remains a complex challenge, as high-grade tumours do not respond to current therapies. Mutations in the isocitrate dehydrogenase (IDH) 1 and 2 genes are among the most common mutations detected in chondrosarcomas and may represent a therapeutic opportunity. The presence of mutated IDH (mIDH) enzymes results in the accumulation of the oncometabolite 2-HG leading to molecular alterations that contribute to drive tumour growth., [Methods]: We developed a personalized medicine strategy based on the targeted NGS/Sanger sequencing of sarcoma samples (n = 6) and the use of matched patient-derived cell lines as a drug-testing platform. The anti-tumour potential of IDH mutations found in two chondrosarcoma cases was analysed in vitro, in vivo and molecularly (transcriptomic and DNA methylation analyses)., [Findings]: We treated several chondrosarcoma models with specific mIDH1/2 inhibitors. Among these treatments, only the mIDH2 inhibitor enasidenib was able to decrease 2-HG levels and efficiently reduce the viability of mIDH2 chondrosarcoma cells. Importantly, oral administration of enasidenib in xenografted mice resulted in a complete abrogation of tumour growth. Enasidenib induced a profound remodelling of the transcriptomic landscape not associated to changes in the 5 mC methylation levels and its anti-tumour effects were associated with the repression of proliferative pathways such as those controlled by E2F factors., [Interpretation]: Overall, this work provides preclinical evidence for the use of enasidenib to treat mIDH2 chondrosarcomas., Supported by the Spanish Research Agency/FEDER (grants PID2022-142020OB-I00; PID2019-106666RB-I00), the ISC III/FEDER (PI20CIII/00020; DTS18CIII/00005; CB16/12/00390; CB06/07/1009; CB19/07/00057); the GEIS group (GEIS-62); and the PCTI (Asturias)/FEDER (IDI/2021/000027)., Consorcio CIBERONC - CB16/12/00390 and Consorcio CIBERER–CB06/07/1009 and CB19/07/00057)]; the Spanish Group for Research on Sarcomas (GEIS) (grant GEIS-62 to R.R.); and the Plan de Ciencia Tecnología e Innovación del Principado de Asturias (PCTI)/FEDER (grant IDI/2021/000027 to R.R.). BG and DM were supported by Severo Ochoa predoctoral fellowships (Plan de Ciencia Tecnología e Innovación del Principado de Asturias/FEDER; grants BP- 20-046 and BP-21–084 respectively). CH was supported by a predoctoral fellowship from the Fundación Científca de la Asociación Española Contra el Cáncer (AECC)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cold plasma-treated medium preferentially eliminates doxorubicin-resistant osteosarcoma cells

  • Tornín, Juan
  • Gallego, Borja
  • Rey, Verónica
  • Murillo, Dzohara
  • Huergo, Carmen
  • Rodríguez, Aída
  • Canal, Cristina
  • Rodríguez, René
Osteosarcoma (OS) is an aggressive bone cancer with poor prognosis, largely due to the limited effectiveness of current treatments such as doxorubicin (DX). Developing ways to overcome DX resistance is a significant clinical challenge. Here, we used two DX-resistant models to study the potential of Cold Plasma Treated Medium (PTM) to prevent DX resistance in OS. During the acquisition of the resistant phenotype upon long-term DX exposure, OS resistant cells became less proliferative, overexpressed the drug resistance-related efflux pump MDR1 and displayed a concomitant loss of SOD2 or GPX1. According to the reduced expression of these antioxidant enzymes, PTM treatment produced higher levels of oxidative express and was more effective in eradicating DX-resistant cells. Moreover, PTM reduced the expression of MDR1, thus sensitizing resistant cells to DX. These findings uncover new vulnerabilities of DX-resistant cells related with their inability to cope with excessive oxidative stress and their dependence on MDR1 that can be exploited using PTM-based treatments to provide new therapeutic approaches for the management of drug resistance in OS., This work was supported by the Agencia Estatal de Investigación (AEI) [MICINN/Fondo Europeo de Desarrollo Regional (FEDER) (grants PID2019-106666RB-I00 and PID2022-142020OB-I00 to R.R. and PID2019- 103892RB-I00/AEI/10.13039/501100011033 to C.C.) and ISC III/FEDER (Consorcio CIBERONC - CB16/12/00390]; the Plan de Ciencia Tecnología e Innovación del Principado de Asturias/FEDER [grant IDI/2021/000027 to R.R. and Severo Ochoa predoctoral fellowships BP‐ 20–046 to B.G. and BP-21–084 to DM]; Fundación Científca de la Asociación Española Contra el Cáncer (AECC) (predoctoral fellowship to CH); CC belongs to SGR2022-1368 and acknowledges Generalitat de Catalunya for the ICREA Academia Award for Excellence in Research., Peer reviewed